home / stock / azn / azn news

AZN News and Press, AstraZeneca PLC From 05/21/24

Stock Information
Company Name: AstraZeneca PLC
Stock Symbol: AZN
Market: NYSE
Website: astrazeneca.com
Menu
AZN AZN Quote AZN Short AZN News AZN Articles AZN Message Board
Get AZN Alerts

News, Short Squeeze, Breakout and More Instantly...
AZN - AstraZeneca projects $80B in revenue by 2030

2024-05-21 08:00:43 ET More on AstraZeneca AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca PLC (AZN) Q1 2024 Earnings Call Transcript AstraZeneca, Amgen release mid-stage data on Tezspire for COPD ...
AZN - AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

Launch of 20 new medicines expected by 2030 Significant growth from existing oncology, biopharmaceuticals and rare disease portfolios Investing in disruptive innovation that will shape the future of medicine and drive long-term growth Decoupling carbon emission...

AZN - AstraZeneca, Amgen release mid-stage data on Tezspire for COPD

2024-05-20 12:49:46 ET More on Amgen, AstraZeneca Amgen Could Become A Real Contender In The Obesity Market Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending AstraZeneca to build $1.5B ADC manufacturing plant in Singapore Bioph...

AZN - AstraZeneca to build $1.5B ADC manufacturing plant in Singapore

2024-05-20 11:12:44 ET More on AstraZeneca AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca PLC (AZN) Q1 2024 Earnings Call Transcript Biopharma M&A surges year over year in Q1 Puma Biotech p...
AZN - New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease

Late-breaking results from the Phase IIa COURSE trial provide insight into TEZSPIRE’s impact on COPD exacerbations in patients with a broad range of eosinophil levels The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstruct...

AZN - SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued?

2024-05-19 15:05:03 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Biopharma M&A surges year ...

AZN - Biopharma M&A surges year over year in Q1

2024-05-19 14:00:55 ET More on pharma companies Novo Nordisk, J&J lead R&D rankings in big pharma: report Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Johnson & Johnson: Buy This Bargain Before It's Gone ...
AZN - Novo Nordisk, J&J lead R&D rankings in big pharma: report

2024-05-18 14:52:07 ET More on GSK, Johnson & Johnson, etc. Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Merck & Co., Inc. (MRK) BofA Securities 2024 Health Care Conference (Transcript) Johnson & Johnson (JNJ) ...

AZN - Puma Biotech surges amid Wyeth victory in Tagrisso patent case

2024-05-17 15:10:02 ET More on Puma Biotechnology Puma Biotechnology: A Story In Flux Heading Into Mid-2024 Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript Puma Biotechnology, Inc. 2024 Q1 - Results - Earnings Call Presentation Puma Biotechno...

AZN - AstraZeneca COVID therapy succeeds in late-stage study for the vulnerable

2024-05-16 10:11:45 ET More on AstraZeneca AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca PLC (AZN) Q1 2024 Earnings Call Transcript AstraZeneca, Pfizer to invest combined $900M+ in France for R&D,...
Previous 10 Next 10